CJC-1295 with DAC: why the rise lasts
Albumin helps a short hormonal message persist. I respect the albumin chemistry; the claims gathered around it face a harder test.
Albumin binding
CJC-1295 copies the active part of growth hormone-releasing hormone, the signal that prompts the pituitary to release growth hormone. The copy has substitutions that slow its breakdown. DAC adds an attachment to albumin, a protein already circulating in blood; without that attachment, Modified GRF (1-29), often called CJC-1295 no-DAC, is short-acting. The review of growth hormone-releasing hormone and its analogues places these designs in their broader pharmacological setting.
The distinction matters before any discussion of results. The prolonged response in the early human papers belongs to the albumin-binding form. Moving its duration across to the no-DAC form loses the very feature that made the experiment possible. That casual interchange of names makes me distrustful of an explanation before it reaches the result.
The prolonged hormonal response
The 2006 healthy-adult study found elevated growth hormone for six days or more and elevated IGF-1 for nine through eleven days after a single administration. Larger study amounts produced greater rises. Those are hormone measurements made under controlled conditions; they establish duration and response, while leaving sleep, strength and recovery untested.
A separate study of healthy men aged 20–40 examined the shape of secretion one week later. Mean growth hormone rose by about 46% and IGF-1 by about 45%, alongside an approximately 7.5-fold rise in the basal level. Pulse frequency and magnitude showed no significant change.
Sustained stimulation sounds as though it ought to produce a smooth output. The continuing bursts complicate that picture. They also make the baseline worth inspecting: a substantial change can happen in the intervals without a corresponding change in the pulses themselves.
A changed blood-protein profile
The response extended beyond the hormone assays. In a 2009 analysis of blood from eleven healthy young men, several serum proteins changed after CJC-1295. Serum is the liquid part of blood left after clotting. Some protein signals correlated with IGF-1, offering possible markers of the hormonal response.
I appreciate the serum-protein study’s broader question. A longer hormonal signal leaves other measurable traces. The correlation does not establish that IGF-1 caused those protein changes, and the analysis did not demonstrate a health improvement. It adds a biological observation rather than a verdict about how someone feels.
Identity required a laboratory
A 2010 report identified CJC-1295 in an unknown seized preparation using liquid chromatography and tandem mass spectrometry. Those techniques separate material and examine its molecular signature. This was analytical work in an anti-doping context, with no patients receiving ordinary treatment.
That paper is a useful interruption to any discussion that treats a compound name as sufficient identification. The authors had to establish what the material contained. A published result from an identified study compound cannot settle the contents of some other preparation.
CJC-1295 community accounts
Community accounts of CJC-1295 describe deeper sleep, easier recovery, puffiness, hand tingling and local irritation. These are anecdotal reports, not clinical evidence that CJC-1295 caused the changes. Mixed use of other substances, unclear compound identity and the DAC/no-DAC confusion make attribution especially difficult. The sleep accounts leave me curious, without a reliable estimate of how often an effect occurs.
CJC-1295 has no approved medical indication. Its small human studies establish a sustained hormone response, while leaving long-term safety inadequately characterized. Fluid retention, blood-sugar effects, immune reactions and the consequences of prolonged IGF-1 elevation remain concerns; the continuing pulses in the secretion study cannot resolve them. CJC-1295 is prohibited in sport at all times.
I relish this experiment’s specificity: an altered molecule, a lasting response and a rhythm that survives. The comparison with ipamorelin and tesamorelin follows what happened when investigators asked for an outcome beyond that curve.